Registered Kenya · PPB

LEVAFORM RESPULES 1.25 MG

LEVOSALBUTAMOL SULPHATE

H2008/19269/621 1.25 MG/2.5 ML

What it does

Levosalbutamol is a medication used to help open the airways in the lungs, making it easier to breathe.

Commonly used for: asthma, chronic obstructive pulmonary disease (COPD)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
H2008/19269/621
Registration date
-
Expiry date
-
Status
Registered
Active ingredient
LEVOSALBUTAMOL SULPHATE
Dosage form
1.25 MG/2.5 ML
Strength
-
Pack size
-
Therapeutic class
-
RxNorm RxCUI
237159
Manufacturer / MAH
Imperial Managed Solutions
Applicant / LTR
-
Country of origin
FOREIGN
Manufacturer location
JW8Q+7R3, kutch Rd, Mlolongo, Kenya

Source: Pharmacy and Poisons Board · fetched 2026-01-28 21:00:33 · updated 2026-07-26 13:42:49

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About this medicine

Levosalbutamol is a medication used to help open the airways in the lungs, making it easier to breathe.

What it treats

  • asthma
  • chronic obstructive pulmonary disease (COPD)

How it works

Levosalbutamol relaxes the muscles in the airways, allowing them to widen and improve airflow.

Who it's for

This medication is for people who have breathing problems such as asthma or COPD.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: levosalbutamol

BNF-referenced

Levosalbutamol is a selective β2-adrenergic agonist used primarily in the management of asthma and other conditions involving bronchoconstriction. It promotes bronchodilation by specifically targeting β2 receptors in airway smooth muscle, leading to relaxation of the bronchial tubes and improved airflow. As a stereoisomer of salbutamol, it is designed to provide effective relief from acute shortness of breath while minimizing side effects associated with non-selective β-agonists.

Indications

  • Asthma
  • Chronic obstructive pulmonary disease (COPD)
  • Bronchospasm

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Levosalbutamol activates β2 adrenergic receptors on airway smooth muscle, which are coupled to the Gs protein. This activation stimulates adenylate cyclase, resulting in increased levels of intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP activates protein kinase A, which inhibits myosin phosphorylation and decreases intracellular calcium concentrations, leading to muscle relaxation. Additionally, increased cAMP levels can inhibit the release of inflammatory mediators from mast cells in the airways, aiding in the management of asthma.

Pharmacodynamics

Levosalbutamol works by relaxing bronchial smooth muscle, thereby increasing airflow and alleviating symptoms of acute shortness of breath. It is effective in providing rapid relief from bronchospasm associated with conditions such as asthma and chronic obstructive pulmonary disease (COPD).

Pharmacokinetics

The pharmacokinetics of levosalbutamol include a rapid onset of action, typically within 15 minutes of administration, with a duration of effect lasting up to 6 hours. It is absorbed well following inhalation, with peak plasma concentrations reached quickly. The drug undergoes hepatic metabolism, primarily through conjugation, and is excreted mainly via the urine.

Adverse effects

  • Tremor
  • Headache
  • Palpitations
  • Tachycardia
  • Hypokalaemia
  • Nausea

Precautions

  • Use with caution in patients with cardiovascular disorders
  • Monitor potassium levels in patients receiving high doses or those with risk of hypokalaemia

Pregnancy

Use in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Levosalbutamol is excreted in breast milk, caution should be exercised when administered to a nursing mother.

Storage

Store below 25°C, protect from light and moisture.

Formulations

  • Inhalation solution
  • Inhaler

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: levosalbutamol

PubChem CID 123600

Molecular formula: C13H21NO3

Mechanism of action

β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks.

Pharmacodynamics

It acts by relaxing smooth muscle in the bronchial tubes to increase air flow and relieve acute shortness of breath.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.